241 related articles for article (PubMed ID: 1630456)
21. Mutagenic analysis of the v-crk oncogene: requirement for SH2 and SH3 domains and correlation between increased cellular phosphotyrosine and transformation.
Mayer BJ; Hanafusa H
J Virol; 1990 Aug; 64(8):3581-9. PubMed ID: 1695251
[TBL] [Abstract][Full Text] [Related]
22. Crk-associated substrate p130(Cas) interacts with nephrocystin and both proteins localize to cell-cell contacts of polarized epithelial cells.
Donaldson JC; Dempsey PJ; Reddy S; Bouton AH; Coffey RJ; Hanks SK
Exp Cell Res; 2000 Apr; 256(1):168-78. PubMed ID: 10739664
[TBL] [Abstract][Full Text] [Related]
23. Identification of domains of the v-crk oncogene product sufficient for association with phosphotyrosine-containing proteins.
Matsuda M; Mayer BJ; Hanafusa H
Mol Cell Biol; 1991 Mar; 11(3):1607-13. PubMed ID: 1705010
[TBL] [Abstract][Full Text] [Related]
24. Mutant mice lacking Crk-II caused by the gene trap insertional mutagenesis: Crk-II is not essential for embryonic development.
Imaizumi T; Araki K; Miura K; Araki M; Suzuki M; Terasaki H; Yamamura K
Biochem Biophys Res Commun; 1999 Dec; 266(2):569-74. PubMed ID: 10600543
[TBL] [Abstract][Full Text] [Related]
25. Direct binding of C-terminal region of p130Cas to SH2 and SH3 domains of Src kinase.
Nakamoto T; Sakai R; Ozawa K; Yazaki Y; Hirai H
J Biol Chem; 1996 Apr; 271(15):8959-65. PubMed ID: 8621540
[TBL] [Abstract][Full Text] [Related]
26. Differential inhibition of signaling pathways by dominant-negative SH2/SH3 adapter proteins.
Tanaka M; Gupta R; Mayer BJ
Mol Cell Biol; 1995 Dec; 15(12):6829-37. PubMed ID: 8524249
[TBL] [Abstract][Full Text] [Related]
27. Downstream of Crk adaptor signaling pathway: activation of Jun kinase by v-Crk through the guanine nucleotide exchange protein C3G.
Tanaka S; Ouchi T; Hanafusa H
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2356-61. PubMed ID: 9122199
[TBL] [Abstract][Full Text] [Related]
28. Alternative splicing generates isoforms of the met receptor tyrosine kinase which undergo differential processing.
Rodrigues GA; Naujokas MA; Park M
Mol Cell Biol; 1991 Jun; 11(6):2962-70. PubMed ID: 1710022
[TBL] [Abstract][Full Text] [Related]
29. A potential SH3 domain-binding site in the Crk SH2 domain.
Anafi M; Rosen MK; Gish GD; Kay LE; Pawson T
J Biol Chem; 1996 Aug; 271(35):21365-74. PubMed ID: 8702917
[TBL] [Abstract][Full Text] [Related]
30. The BCR/ABL oncogene alters interaction of the adapter proteins CRKL and CRK with cellular proteins.
Uemura N; Salgia R; Li JL; Pisick E; Sattler M; Griffin JD
Leukemia; 1997 Mar; 11(3):376-85. PubMed ID: 9067577
[TBL] [Abstract][Full Text] [Related]
31. The v-Crk oncogene enhances cell survival and induces activation of protein kinase B/Akt.
Stam JC; Geerts WJ; Versteeg HH; Verkleij AJ; van Bergen en Henegouwen PM
J Biol Chem; 2001 Jul; 276(27):25176-83. PubMed ID: 11323409
[TBL] [Abstract][Full Text] [Related]
32. Activation of c-Src in cells bearing v-Crk and its suppression by Csk.
Sabe H; Okada M; Nakagawa H; Hanafusa H
Mol Cell Biol; 1992 Oct; 12(10):4706-13. PubMed ID: 1383688
[TBL] [Abstract][Full Text] [Related]
33. The SH2- and SH3-containing Nck protein transforms mammalian fibroblasts in the absence of elevated phosphotyrosine levels.
Chou MM; Fajardo JE; Hanafusa H
Mol Cell Biol; 1992 Dec; 12(12):5834-42. PubMed ID: 1280326
[TBL] [Abstract][Full Text] [Related]
34. Expression of the v-crk oncogene product in PC12 cells results in rapid differentiation by both nerve growth factor- and epidermal growth factor-dependent pathways.
Hempstead BL; Birge RB; Fajardo JE; Glassman R; Mahadeo D; Kraemer R; Hanafusa H
Mol Cell Biol; 1994 Mar; 14(3):1964-71. PubMed ID: 7509449
[TBL] [Abstract][Full Text] [Related]
35. Characterization of human and mouse c-fes cDNA clones and identification of the 5' end of the gene.
Alcalay M; Antolini F; Van de Ven WJ; Lanfrancone L; Grignani F; Pelicci PG
Oncogene; 1990 Mar; 5(3):267-75. PubMed ID: 2179816
[TBL] [Abstract][Full Text] [Related]
36. Molecular cloning of a developmentally regulated brain protein, chicken drebrin A and its expression by alternative splicing of the drebrin gene.
Kojima N; Shirao T; Obata K
Brain Res Mol Brain Res; 1993 Jul; 19(1-2):101-14. PubMed ID: 8361332
[TBL] [Abstract][Full Text] [Related]
37. Molecular cloning and characterization of PEA3, a new member of the Ets oncogene family that is differentially expressed in mouse embryonic cells.
Xin JH; Cowie A; Lachance P; Hassell JA
Genes Dev; 1992 Mar; 6(3):481-96. PubMed ID: 1547944
[TBL] [Abstract][Full Text] [Related]
38. Quail neuroretina c-Rmil(B-raf) proto-oncogene cDNAs encode two proteins of 93.5 and 95 kDa resulting from alternative splicing.
Eychène A; Barnier JV; Dézélée P; Marx M; Laugier D; Calogeraki I; Calothy G
Oncogene; 1992 Jul; 7(7):1315-23. PubMed ID: 1620546
[TBL] [Abstract][Full Text] [Related]
39. Activation of the focal adhesion kinase signaling pathway by structural alterations in the carboxyl-terminal region of c-Crk II.
Zvara A; Fajardo JE; Escalante M; Cotton G; Muir T; Kirsch KH; Birge RB
Oncogene; 2001 Feb; 20(8):951-61. PubMed ID: 11314030
[TBL] [Abstract][Full Text] [Related]
40. Analysis of cDNAs of the proto-oncogene c-src: heterogeneity in 5' exons and possible mechanism for the genesis of the 3' end of v-src.
Dorai T; Levy JB; Kang L; Brugge JS; Wang LH
Mol Cell Biol; 1991 Aug; 11(8):4165-76. PubMed ID: 1712905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
